Entries |
Document | Title | Date |
20080216182 | Animal Model for the Human Immune System, and Method for Producing the Same - In a method for preparing an animal model for the human immune system in a non-human mammal, human stem cells with hematopoietic potential are transplanted into a non-human mammal. The non-human mammal is conditioned with cell culture supernatant of a culture of human cell lines, cells and/or tissue. The cell culture supernatant is derived from cell lines producing cytokines and other molecular mediators. | 09-04-2008 |
20080216183 | Model of infantile spasm syndrome - Provided are non-human mammals treated with doxorubicin, lipopolysaccharide (LPS), and p-chlorophenylalanine (PCPA), where the mammal exhibits a symptom characteristic of infantile spasms. Also provided are methods of making a non-human mammal exhibit a symptom of infantile spasms. Additionally, methods are provided for screening a compound for the potential to attenuate a symptom of infantile spasms. | 09-04-2008 |
20080250512 | Restless Legs Syndrome and Periodic Limb Movement Disorder Model Animal - The present invention provides a model animal of Restless Legs Syndrome (RLS) and Periodic Limb Movement Disorder (PLMD). As a result of intraperitoneal administration to a mouse of the plasma constituents in peripheral blood collected from renal failure patients in whom RLS and PLMD were diagnosed, it was found that the mouse remarkably showed behavior pathognomonic in these diseases, and hence can be used as a model mouse of these diseases. The model animal of the present invention can be used for not only the identification of a causative substance of RLS and PLMD, but also the development and evaluation of a diagnostic method and therapy for these diseases. | 10-09-2008 |
20080250513 | LACTOBACILLUS N-DEOXYRIBOSYL TRANSFERASES, CORRESPONDING NUCLEOTIDE SEQUENCES AND THEIR USES - The invention concerns novel polypeptides and their fragments, isolated from | 10-09-2008 |
20080295189 | Construction of Arterial Occlusive Disease Animal Model | 11-27-2008 |
20080301824 | Parkin interacting polypeptides and methods of use - The invention provides parkin binding polypeptides and encoding nucleic acids. The invention also provides antibodies specific for the parkin binding polypeptides. The invention additionally provides methods of detecting a parkin binding polypeptide and detecting a nucleic acid encoding a parkin binding polypeptide. The invention further provides methods of using a parkin binding polypeptide. In one embodiment, the invention provides a method of identifying a candidate drug for treating Parkinson's disease by contacting a parkin binding polypeptide with one or more compounds and identifying a compound that alters the activity of the parkin binding polypeptide. | 12-04-2008 |
20090013420 | Psmcs as Modifiers of the Rb Pathway and Methods of Use - Human PSMC genes are identified as modulators of the RB pathway, and thus are therapeutic targets for disorders associated with defective RB function. Methods for identifying modulators of RB, comprising screening for agents that modulate the activity of PSMC are provided. | 01-08-2009 |
20090019558 | PGDS AS MODIFIERS OF THE PTEN PATHWAY AND METHODS OF USE - Human PGD genes are identified as modulators of the PTEN pathway, and thus are therapeutic targets for disorders associated with defective PTEN function. Methods for identifying modulators of PTEN, comprising screening for agents that modulate the activity of PGD are provided. | 01-15-2009 |
20090025096 | P4HAS AS MODIFIERS OF THE IGFR PATHWAY AND METHODS OF USE - Human P4HA genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of P4HA are provided. | 01-22-2009 |
20090038021 | Novel clock gene and application of the same - It is intended to provide a novel gene encoding a new protein which interacts with BMAL2 protein. Namely, a novel gene comprising any one of the following DNAs (a) to (e): (a) a DNA comprising any one of the base sequences represented by SEQ ID NOS: 1 to 4; (b) a DNA that comprises a base sequence derived from the base sequence of the DNA (a) by deletion, substitution or addition of one to several bases and encodes a protein interacting with BMAL2 protein; (c) a DNA that comprises a base sequence derived from the base sequence of the DNA (a) by deletion, substitution or addition of one to several bases and is hybridizable with the DNA (a) under stringent conditions; (d) a DNA that comprises a base sequence derived from the base sequence of the DNA (a) by deletion, substitution or addition of one to several bases and has a homology of 90% or higher with the DNA (a); and (e) a DNA comprising a base sequence that is complementary to any one of the DNAs (a) to (d). | 02-05-2009 |
20090077677 | MAMMALIAN GRAINYHEAD TRANSCRIPTION FACTORS - The present invention relates generally to diagnostic and therapeutic agents. More particularly, the present invention provides mammalian transcription factors which function in the modulation of expression of genetic sequences. The present invention further provides nucleic acid molecules encoding the transcription factors as well as nucleic acid and/or proteinaceous molecules with which the transcription factors interact. The transcription factors of the present invention or molecules interacting with same may be used inter alia in the generation of a range of diagnostic and therapeutic agents for a range of conditions. | 03-19-2009 |
20090100534 | MUSCLE LAMIN A/C INTERACTING PROTEIN, GENE ENCODING SAME, AND USES THEREFOR - Peptide sequences of human and murine muscle lamin A/C interacting protein and nucleotide sequences encoding same and are provided. Uses of the muscle lamin A/C interacting protein are also provided herein. | 04-16-2009 |
20090138976 | ANIMAL MODEL FOR HEPATITIS C VIRUS INFECTION - The current document relates to transgenic rodents that have a nucleic acid molecule encoding a hepatocyte mitogen polypeptide. | 05-28-2009 |
20090183268 | METHODS AND SYSTEMS FOR MEDICAL SEQUENCING ANALYSIS - Disclosed are methods of identifying elements associated with a trait, such as a disease. The methods can comprise, for example, identifying the association of a relevant element (such as a genetic variant) with a relevant component phenotype (such as a disease symptom) of the trait, wherein the association of the relevant element with the relevant component phenotype identifies the relevant element as an element associated with the trait, wherein the relevant component phenotype is a component phenotype having a threshold value of severity, age of onset, specificity to the trait or disease, or a combination, wherein the relevant element is an element having a threshold value of importance of the element to homeostasis relevant to the trait, intensity of the perturbation of the element, duration of the effect of the element, or a combination. The disclosed methods are based on a model of how elements affect complex diseases. The disclosed model is based on the existence of significant genetic and environmental heterogeneity in complex diseases. Thus, the specific combinations of genetic and environmental elements that cause disease vary widely among the affected individuals in a cohort. The disclosed model is an effective, general experimental design and analysis approach for the identification of causal variants in common, complex diseases by medical sequencing. The disclosed model and the disclosed methods based on the model can be used to generate valuable and useful information. | 07-16-2009 |
20090217394 | Diabetes Model Animal - The present invention relates to a diabetes animal model. Specifically, the present invention relates to a transgenic nonhuman animal, into which recombinant DNA comprising a gene encoding a diphtheria toxin receptor and an insulin promoter for regulating expression of the above gene has been introduced. | 08-27-2009 |
20090241205 | METHOD FOR IDENTIFYING CRMP MODULATORS - The present invention refers to a method for identifying a modulator of CRMP suitable for the prevention, alleviation or/and treatment of CRMP-associated diseases. | 09-24-2009 |
20090241206 | METHODS FOR CLONING FERRETS AND TRANSGENIC FERRET MODELS FOR DISEASES - The invention provides a transgenic Mustelidae in which a gene associated with a human disease or condition comprises a targeted genetic modification, and uses thereof. Also provided is a method to cryopreserve Mustelidae embryos or cells, and to enhance the number of live offspring from cryopreserved Mustelidae embryos. | 09-24-2009 |
20090300776 | COMPOSITIONS FOR PREVENTING, REDUCING OR TREATING KERATINOCYTE-MEDIATED INFLAMMATION - The present invention relates to the field of epidermal repair. More particularly, the invention concerns the use of a molecule able to inhibit a heteromeric receptor comprising OSMRβ as a subunit, for the preparation of a composition for inhibiting the expression of inflammatory factors by the keratinocytes. In particular, the invention concerns the use of antagonists and/or expression inhibitors of OSM, IL-17, TNFα, IL-31, IFN-γ, and/or the OSMRβ subunit, for the preparation of cosmetic or dermatologic compositions, especially for treating inflammatory skin diseases. | 12-03-2009 |
20090300777 | Novel apoptosis inducing factor and method of inducing apoptosis using the same - The purpose of the present invention is to provide a system in which an apoptosis-inducing factor is expressed in an expression promoter-dependent manner, which is not a system wherein a toxin is introduced externally, and a novel protein that can enhance an apoptosis signal used in the system. | 12-03-2009 |
20090300778 | Neutral Sphingomyelinase-E and Its Use - The present invention provides a neutral sphingomyelinase-3 (nSMase3), a nucleic acid encoding said nSMase3, a vector containing said nucleic acid, and cells and non-human organisms transformed or transfected with said nucleic acid sequence or vector. The invention furthermore relates to the use of said nSMase3 as pharmaceutical or diagnostic agent. Test systems for candidate active agents for their therapeutic potential in diseases connected with nSMase3 are also provided. | 12-03-2009 |
20100005534 | SASPASE KNOCKOUT ANIMAL - Knockout animals in which a gene encoding a SASPase has been deleted (hereinafter, referred to as SASPase KO animals) are provided. The SASPase KO animals deficient in expression of functional SASPase were produced by deleting a gene encoding a stratified epithelium-specific protease, SASPase, through targeted disruption. The SASPase KO animals showed a significant increase in wrinkles on the sides of the body and so on. The SASPase KO animals find utility as animal models of wrinkles. | 01-07-2010 |
20100050278 | Application of Actin-Binding Protein to Disease Associated With Cell Motility - It is intended to identity a protein involved in a molecular mechanism between Akt and cell motility as well as to elucidate its function and find its application. In the present teachings, for achieving the above object, protein or partial peptide thereof containing an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID: 2 is utilized in the screening of a compound or a salt thereof that activates or inhibits any of cell motility, cell migration and angiogenesis. | 02-25-2010 |
20100058488 | PROTEIN FORMULATIONS COMPRISING S1-5 - The present inventors discovered that knockout mice whose S1-5 gene function is lost develop age-related diseases or symptoms. In such knockout mice, bone mineral content, bone mineral density, and bone strength were found to be decreased, and the number of osteoclasts in bone tissues was found to be increased. Analysis of osteoclast-forming ability using bone marrow cells derived from the knockout mice revealed that osteoclast-forming ability is enhanced and osteoclasts are larger in the knockout mice than in wildtype mice. When purified S1-5 protein was added to this in vitro system, osteoclast-forming ability was inhibited. Furthermore, administration of purified S1-5 protein to osteoporotic model mice showed that this protein has the effect of improving osteoporosis. The above findings demonstrate that S1-5 protein is useful for treating and preventing age-related diseases such as osteoporosis. | 03-04-2010 |
20100132058 | Methods and materials for determining pain sensitivity and predicting and treating related disorders - Methods of treating somatosensory disorders and modulating production of proinflammatory cytokines by administering to a subject an effective amount of a COMT modulator, ADRB2 modulator, ADRB3 modulator or combinations thereof are provided. Methods of predicting effective pharmacological therapies for a subject afflicted with a somatosensory disorder by determining a genotype of the subject with regard to a gene selected from the group consisting of COMT, ADRB2, ADRB3, and combinations thereof are further provided. Methods of determining pain responses or pain perception and predicting susceptibility of a subject to develop related disorders, such as somatosensory disorders and somatization, by determining a genotype of the subject with regard to a gene selected from the group consisting of COMT, ADRB2, ADRB3, and combinations thereof are further provided. | 05-27-2010 |
20100138943 | IDENTIFICATION OF GROUP OF HYPERTENSION-SUSCEPTIBILITY GENES - A genetic marker including a SNP which can be used for assessing the risk of developing hypertension, a polynucleotide for assessing the risk of developing hypertension which can be used as a primer or probe for detecting the genetic marker, a method for assessing the risk of developing hypertension using the SNP, a microarray for assessing the risk of developing hypertension which is used for genotyping of the SNP, a kit used in the method for assessing the risk of developing hypertension, and the like. | 06-03-2010 |
20100146649 | Purkinje Cell-Tropic Viral Vector - The present invention relates to a Purkinje cell-tropic viral vector in which a modified L7 promoter and a therapeutic gene are operably linked to a virus-based plasmid vector. | 06-10-2010 |
20100154069 | PIG MODEL - The present invention relates to a genetically modified pig comprising at least one site for integration of at least one transgene. The invention also pertains to a porcine embryo, blastocyst, foetus, donor cell and/or cell nucleus, derived from said genetically modified pig. In another aspect, the invention relates to any genetically modified porcine blastocyst, wherein the genetically modified genome comprises at least one site for integration of at least one transgene. | 06-17-2010 |
20100169989 | Use of Follistatin-Like Related Gene (FLRG) to Increase Muscle Mass - The present relates to use of follistatin-like related gene (FLRG) to increase muscle mass in a subject. As such, methods of ameliorating the severity of a pathologic condition characterized, at least in part, by a decreased amount, development or metabolic activity of muscle are provided. In addition transgenic non-human mammals expressing FLRG and having increased muscle mass as compared to a corresponding mammal having a myostatin-null mutation or a decreased level of myostatin are provided. | 07-01-2010 |
20100186101 | DIAGNOSIS AND TREATMENT OF FERTILITY CONDITIONS USING A SERINE PROTEASE - The invention relates to the use of a serine protease, which is specifically expressed in association with embryo implantation and placentation in pregnant uterus in the evaluation of fertility and monitoring of early pregnancy, placental development and function, fetal development, parturition, and conditions such as pre-eclampsia, intrauterine growth restriction, early abortion, abnormal uterine bleeding, endometriosis, and cancers. | 07-22-2010 |
20100199361 | Role of Proteoglycans in Drug Dependence - The invention provides methods of preventing or treating drug addiction, or ameliorating the craving for an addictive drug, as well as compounds, peptides, and pharmaceutical compositions that may be used to prevent or treat drug addiction or ameliorate the craving for an addictive drug. The invention also provides methods for identifying agents that may be used to prevent or treat drug addiction, or ameliorate the craving for an addictive drug. | 08-05-2010 |
20100199362 | WNT LIGANDS INVOLVED IN BLOOD-BRAIN BARRIER DEVELOPMENT AND USES THEREFOR - Provided are methods of diagnosing and treating vascular disorders of the CNS or disorders of the blood-brain barrier comprising the use of Wnt ligands involved in the canonical Wnt signaling pathway. | 08-05-2010 |
20100229249 | IDENTIFICATION OF GROUP OF HYPERTENSION-SUSCEPTIBILITY GENES - Provided in the present invention is a genetic marker including a SNP which can be used for assessing the risk of developing hypertension, a polynucleotide for assessing the risk of developing hypertension which can be used as a primer or probe for detecting the genetic marker, a method for assessing the risk of developing hypertension using the SNP, a microarray for assessing the risk of developing hypertension which is used for genotyping of the SNP, a kit used in the method for assessing the risk of developing hypertension, and the like. | 09-09-2010 |
20100229250 | TREATMENT AND PREVENTION OF ISCHEMIC BRAIN INJURY - The invention provides methods of identifying agents for treating and preventing ischemic brain injury. | 09-09-2010 |
20100229251 | Methods and Compositions for Detecting and Treating End-Stage Cardiomyopathy Using Claudin-5 - The present invention provides a method for diagnosis end-stage cardiomyopathy includes measuring expression of claudin-5 levels in a patient suspected of suffering from end-stage cardiomyopathy as well as a method for treating end-stage cardiomyopathy includes administering an effective amount of a composition effectively upregulates the claudin-5 or inhibits degradation of claudin-5 | 09-09-2010 |
20100235931 | Novel Neurological Function of mPKCI - Wildtype and mice lacking the gene encoding PKCI/HINT 1 (PKC | 09-16-2010 |
20100251394 | TREATMENT AND PREVENTION OF ISCHEMIC BRAIN INJURY - The invention provides methods of identifying agents for treating and preventing ischemic brain injury. | 09-30-2010 |
20100263065 | MATERIALS AND METHODS FOR GENE MEDIATED THERAPY OF PSYCHIATRIC DISORDERS - The invention provides materials and methods for p11-mediated therapy of psychiatric disorders. The invention provides vectors for increasing p11 expression and methods of treating a mammal with one or more symptoms of a psychiatric disorder. The invention also provides methods for improving a mammal's responsiveness to treatment for a psychiatric disorder. The invention further provides model animals for depression and depression therapy. | 10-14-2010 |
20100275277 | INFECTED NAIL OF ANIMAL INFECTED WITH FUNGUS - The invention can produce an infected nail of an animal and an infected animal model in which the nail plate and nail bed of the nail are sufficiently infected with a superficial fungus which were difficult to be produced in the past, and provides an evaluation method useful for development of a therapeutic agent for intractable infectious diseases such as tinea unguium using the nail and the infected animal model. For producing the infected nail of an animal and the infected animal model infected with a superficial fungus, an immunosuppressive component is administered to an animal in advance to decrease immunocompetence, and then, a superficial fungus is inoculated into the animal, whereby the infected nail of an animal and the infected animal model reflecting clinical manifestation in which the nail plate and nail bed of the nail are sufficiently infected with the superficial fungus can be produced with good reproducibility in a short period of time. | 10-28-2010 |
20100281550 | FACTOR INVOLVED IN LATENT INFECTION WITH HERPESVIRUS, AND USE THEREOF - Disclosed are a protein and a gene each of which is a factor involved in latent infection with a herpesvirus. An antibody against the factor was detected in approximately 50% of patients suffering from mental disorders, whereas the antibody was hardly detected in healthy persons. Further, a mouse having SITH-1 introduced therein developed a mental disorder such as a manic-depressive illness or depression-like disorder. Based on these findings, it is possible to provide a method for objectively determining a mental disorder and an animal model of a mental disorder. | 11-04-2010 |
20100287630 | MODELS FOR VACCINE ASSESSMENT - The present invention is directed to methods for constructing and using in vivo and in vitro models of aspects of human immunity and, in particular, construction of a human immune system model for the testing of, for example, vaccines, adjuvants, immunotherapy candidates, cosmetics, drugs, biologics and other chemicals. The present invention comprises both in vivo and in vitro models of aspects of human immunity that are useful for assessing the interaction of substances with the immune system, and thus can be used to accelerate and improve the accuracy and predictability of, for example, vaccine, drug, biologic, immunotherapy, cosmetic and chemical development. The invention is also useful for the generation of human monoclonal and polyclonal antibodies. | 11-11-2010 |
20100299768 | Reversible siRNA-Based Silencing of Mutant and Endogenous Wild-Type Huntingtin Gene and its Application for the Treatment of Huntington's Disease - Isolated double-stranded short interfering nucleic acid molecules inhibiting the expression of endogenous wild-type and exogenous human mutant huntintin genes in cells of a non-human mammal which are expressing both said huntingtin genes, and their application for the treatment of Huntington's disease as well as to study Huntington's disease in rodent models. | 11-25-2010 |
20110030073 | THERAPEUTIC TARGETS AND MEDICAMENTS INVOLVING P230/GOLGIN-245 - The present invention relates generally to the field of cell biology and in particular the cellular processes surrounding inflammation. Even more particularly, the present invention provides targets for medicaments useful in reducing levels of TNF-alpha, an extracellular pro-inflammatory mediator. The medicaments are therefore useful in modulating inflammatory responses. Model inflammatory disease systems also form part of the present invention. | 02-03-2011 |
20110035818 | DIAGNOSTIC MARKER AND PLATFORM FOR DRUG DESIGN IN MYOCARDIAL INFARCTION AND HEART FAILURE - Methods for determining the susceptibility of an individual to a heart condition, post myocardial infarction, comprising detecting the presence of an amino acid change in the sequence of the hemopexin domain of MMP-9 (Matrix Metalloproteinase 9), the presence of an amino acid change in said domain being indicative of susceptibility to said heart condition, post myocardial infarction is described, together with methods for drug design. | 02-10-2011 |
20110041193 | NON-HUMAN MAMMAL MODEL OF EPILEPSY - The present invention provides a genuine epilepsy model animal as an improvement over conventional epilepsy model animals which are socalled seizures model animals mainly causing seizure attacks to be forcibly induced. Also provided is a method that allows for easy identification of the recombinants. | 02-17-2011 |
20110047632 | Fibrinogen immune complexes to diagnose and guide therapy in rheumatoid arthritis - Compositions and methods are provided for prognostic classification of rheumatoid arthritis disease patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. | 02-24-2011 |
20110047633 | Control of Exocrine Pancreatic Function Using Bone Morphogenetic Proteins - Methods are described for controlling exocrine pancreatic function, for reducing the level of amylase in the blood, and for treating pancreatitis in an individual comprising administering to the individual a bone morphogenetic protein (BMP). Methods for identifying candidate molecules for use in treating diabetes are also described. | 02-24-2011 |
20110055939 | METHOD FOR INTRODUCING FOREIGN GENE INTO EARLY EMBRYO OF PRIMATE ANIMAL AND METHOD FOR PRODUCING TRANSGENIC PRIMATE ANIMAL COMPRISING SUCH METHOD - An object of the present invention is to provide a method for introducing a gene into an embryo for production of a human disease model primate animal using a non-human primate animal such as a marmoset. The present invention relates to a method for introducing a foreign gene into an early embryo of a non-human primate animal, which comprises placing early embryos of a non-human primate in a 0.2 M to 0.3 M sucrose solution, so as to increase the volume of the perivitelline spaces, and then injecting a viral vector containing a human foreign gene operably linked to a promoter into the perivitelline spaces of the early embryos. | 03-03-2011 |
20110061115 | Lung rpogenitor cells, assays, and uses thereof - Substantially enriched mammalian lung endothelial and epithelial progenitor cell populations are provided. Methods are provided for the isolation and in vivo differentiation of such lung progenitor cells. The progenitor cells are obtained from lung tissue, including fetal and adult tissues. The cells are useful in transplantation, for experimental evaluation, and as a source of lineage and cell specific products, including mRNA species useful in identifying genes specifically expressed in these cells, and as targets for the discovery of factors or molecules that can affect them. | 03-10-2011 |
20110067123 | MAO-B ELEVATION AS AN EARLY PARKINSON'S DISEASE BIOMARKER - This invention pertains to development of a new animal model for Parkinson's Disease (PD) and to the discovery that elevated monoamine oxygenase B (MOA-B) expression and/or activity is a strong prognostic indicator for the disease. Accordingly, in certain embodiments, methods are provided for identifying a mammal at risk for Parkinson's disease. The methods typically involve determining level of expression or activity of monoamine oxidase B (MAO-B) in a sample from the mammal wherein an elevated level of MAO-B expression and/or activity as compared to a control (reference) is an indicator that the mammal has an increased likelihood of developing Parkinson's disease. | 03-17-2011 |
20110078804 | Angiogenin and Amyotrophic Lateral Sclerosis - Methods and compositions for treating neurodegenerative disorders are provided. Transgenic animal models of neurodegenerative disorders are provided. Knockout animal models of neurodegenerative disorders are also provided. Mutant angiogenin polypeptides are also provided. | 03-31-2011 |
20110088103 | ALLERGIC DISEASE MODEL ANIMALS - The object of the present invention is to provide a mouse model for allergic diseases such as atopic dermatitis, and a dermatitis mouse model with impaired skin-barrier function. The present inventors found out that a mouse that has been caused to completely lose the function of expressing profilaggrin protein and filaggrin protein by entirely or partially disrupting the endogenous gene encoding filaggrin by a genetic mutation such as deletion or replacement, can be used as a mouse model for allergic diseases or atopic dermatitis wherein the skin-barrier function has been impaired. | 04-14-2011 |
20110099645 | ANIMAL MODEL FOR CIGARETTE-SMOKE-INDUCED ATHEROSCLEROSIS AND RELATED METHODS - Provided herein are non-human animal models and related methods useful for the identification, characterization, and analysis of the effects of environmental stimuli on the development and progression of pathological conditions. The environmental stimuli can include, but are not limited to, exposure to tobacco (e.g., cigarette, etc.) smoke. Exemplary pathological conditions include, but are not limited to, atherosclerosis, other cardiovascular disease (CVD), and the like. Also provided herein are non-human animal models and related methods useful for the identification, characterization, and analysis of pharmaceutical compounds, compositions, and/or formulations that can be used to prevent or treat a given pathological condition brought on by exposure to a given environmental condition. | 04-28-2011 |
20110119775 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF - The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a hydrazide-containing compound to a non-human animal in an amount sufficient to inhibit CFTR. | 05-19-2011 |
20110131669 | GANGLIOSIDE EPITOPES FOR TREATING GUILLAIN-BARRE SYNDROME - Disclosed are compositions and methods for treating Guillain-Barré syndrome (GBS) in a subject that involves neutralizing specific pathogenic anti-glycolipid antibodies in the circulation of the subject. This can involve administering to the subject a molecular mimic of a ganglioside that serves as a specific competitive inhibitor for anti-ganglioside antibodies in the circulation. Also disclosed is an animal model of GBS having anti-ganglioside antibodies in the circulation. | 06-02-2011 |
20110173709 | ECTOPIC, ORTHOTOPIC MODEL FOR REVASCULARIZATION AND TUMOR ASSESSMENT - Improved vascularization and tumor models, comprising a test animal having a dorsal skin window chamber, and an exogenous tissue sample implanted ectopically in the skin within the window chamber, are described, as are methods of using the models. | 07-14-2011 |
20110197290 | METHODS AND MATERIALS FOR PRODUCING TRANSGENIC ARTIODACTYLS - Swine animal models comprising a genomic disruption of an endogenous gene chosen from the group consisting of a Low-Density Lipoprotein Receptor gene LDLR, Duchene's Muscular Dystrophy (DMD) gene, and hairless gene (HR). Methods of preparing transfected cells useful for making a transgenic animal comprising exposing a first group of cells to a transfection agent and reseeding the group with additional cells that have not been exposed to the agent. The transgenic animals are useful for medical and scientific animal models of human diseases and conditions, as well as sources for cells, tissues, and biomaterials. | 08-11-2011 |
20110225661 | METHOD FOR TREATING AND PREVENTING RADIATION DAMAGE USING GENETICALLY MODIFIED MESENCHYMAL STEM CELLS - A method of treating or preventing radiation damage by administering to a patient in need of treatment at least one therapeutically effective amount of a mesenchymal stem cell genetically altered to secrete extracellular superoxide dismutase is provided. Also provided is a therapeutic for treating and/or preventing radiation related or damage by similar agents, the therapeutic contains genetically modified mesenchymal stem cells capable of secreting extracellular superoxide dismutase. | 09-15-2011 |
20110252487 | COMPOSITION FOR INDUCING TH2 CELL, THERAPEUTIC COMPOSITION FOR TH2-TYPE DISEASE, AND USE OF SAME - The present invention provides a complex of an antigen and IgE binding to the antigen, a composition including an antigen and IgE binding to the antigen, and a method of using the complex or the composition. With the present invention, it is possible to induce naive T cells to develop into Th2 cells. Moreover, the present invention clarified a working mechanism of a Th2-type immune response, particularly a production mechanism of early IL-4. With use of the present invention, it is possible to provide a technique of treating and preventing Th2-type diseases. | 10-13-2011 |
20110258713 | COMPOSITIONS AND METHODS FOR RE-PROGRAMMING CELLS WITHOUT GENETIC MODIFICATION - The present inventions are directed to compositions and methods regarding the reprogramming of biological samples (such as cells) without introducing exogenous genes to the samples. In particular, the present inventions are directed to transducible materials that are capable of transducing into the biological samples but are not genes or causing genetic modifications. The present inventions also are directed to methods of reprogramming the path of biological samples or treating diseases using the tranducible compositions thereof. | 10-20-2011 |
20110265194 | THEM5-MODIFIED MODELS OF NON-ALCOHOLIC FATTY LIVER DISEASE - The invention provides a new reproducible genetically-modified mouse model for the study of non-alcoholic fatty liver disease. In particular, the invention concerns the study of non-alcoholic fatty liver disease in an THEM5 knockout mouse model and its use in drug discovery and research. | 10-27-2011 |
20110271356 | HCV ENTRY FACTOR, OCCLUDIN - The human Occludin protein is identified as an essential Hepatitis C Virus (HCV) cell entry factor. Occludin is shown to render murine and other non-human cells infectable with HCV and to be required for HCV—susceptibility of human cells. Associated methods for inhibiting HCV infection, transgenic animal models for HCV pathogenesis, methods of identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin, and HCV inhibitory agents are also disclosed. Kits and cell culture compositions useful for identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin are also provided. | 11-03-2011 |
20110283371 | Stem Cell Modified Animal Model for Aging-Related Degenerations, Stem Cell Based Methods and Compositions for Extending Lifespan and Treating SLE-Like Autoimmune Diseases - This invention discloses a stem cell modified animal model useful as a research tool for investigating aging-related degeneration processes and treatments. The animal model is preferably a rodent subcutaneously transplanted with a mesenchymal stem cell capable of generating a functional bone or marrow element. Also provided are a method for extending the lifespan and improving the quality of life of a subject by subcutaneously transplanting a plurality of mesenchymal stem cells to the subject, wherein the mesenchymal stem cells are capable of generating a functional bone or marrow element. Compositions and source of stem cells suitable for use with the methods of this invention, including stem cells from human exfoliated deciduous teeth (SHED), are also disclosed. Further disclosed is a method for identifying progenitor bone marrow mesenchymal stem cells, and a method for treating SLE-like autoimmune diseases by infusion of mesenchymal stem cells. | 11-17-2011 |
20110289608 | ANTISENSE MODULATION OF INTERLEUKINS 17 AND 23 SIGNALING - Provided are antisense oligonucleotides and other agents that target and modulate IL-17 and/or IL-23 signaling activity in a cell, compositions that comprise the same, and methods of use thereof. Also provided are animal models for identifying agents that modulate 17 and/or IL-23 signaling activity. | 11-24-2011 |
20110321180 | COMPOSITIONS AND METHODS TO GENERATE PILOSEBACEOUS UNITS - The invention provides compositions and methods to generate pilosebaceous units. In one aspect, the invention comprises a biocompatible scaffold and an effective amount of dermal and epidermal precursor cells. | 12-29-2011 |
20110321181 | DEVICE TO BE PLACED IN BLOOD VESSEL, ANGIOSTENOSIS MODEL USING SAME AND METHOD FOR MAKING MODEL - An indwelling vascular device is constructed such that a vascular stenosis model can be controlled from the partial stenosis to the total occlusion. There is also described a vascular stenosis model of such non-human animal, and a method for making the same. The model can be used for diagnosis or therapy of a disease resulting from the stenosis or total occlusion in a blood vessel or further for the development of therapeutic approaches. The indwelling vascular device includes a device substrate containing a metal and/or metal compound which elutes toxic metal ions at least from a surface thereof and having a structure ensuring a vascular flow immediately after indwelling in a blood vessel, and a polymer coating layer formed on at least a metal and/or metal compound containing surface of the substrate. | 12-29-2011 |
20120030779 | COMPOSITIONS AND METHODS FOR DETECTING, TREATING, OR PREVENTING REDUCTIVE STRESS - Disclosed herein is a non-human animal model of protein aggregation cardiomyopathy. Also disclosed are compo-sitions and methods of treating or preventing a condition in a subject caused or exacerbated by reductive stress. Also disclosed are compositions and methods of predicting, detecting, or monitoring reductive stress in a subject. | 02-02-2012 |
20120060230 | METHODS AND COMPOSITIONS FOR MODIFICATION OF A HLA LOCUS - Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator. | 03-08-2012 |
20120060231 | METHOD AND KIT FOR EVALUATION OF PREDISPOSITION TO DEVELOPMENT OF OBESITY, ANTI-OBESITY AGENT AND METHOD FOR SCREENING THEREOF, NON-HUMAN ANIMAL, ADIPOSE TISSUE, ADIPOCYTE, METHOD FOR PRODUCTION OF TRANSGENIC MOUSE, ANTIGEN, AND ANTIBODY - It is an object of the present invention to provide a method of evaluating whether or not a subject has a predisposition to obesity or an obesity-related condition or disease, a kit for conducting the method, an anti-obesity drug having an effect of preventing or treating obesity or an obesity-related condition or disease, a method of screening the anti-obesity drug, a non-human animal having a deficiency in the gene associated with obesity, and an adipose tissue or adipocyte of the animal. | 03-08-2012 |
20120066779 | HEPATITIS C RECEPTOR PROTEIN CD81 - The present invention relates to the use of CD81 protein and polynucleic acid in the therapy and diagnosis of hepatitis C and pharmaceutical compositions, animal models and diagnostic kits for such purposes. | 03-15-2012 |
20120066780 | HUMANIZED NSG MOUSE, METHOD OF PRODUCING THE SAME AND USE THEREOF - A mouse model in which human fetal thymus and human fetal bone fragments are transplanted into NSG mice, a method of producing the same, and a use thereof. | 03-15-2012 |
20120073002 | PREVENTION AND TREATMENT OF BLOOD COAGULATION-RELATED DISASES - Provided herein is an animal having a persistent hypercoagulable state by implanting a cell, for example a tumor cell, in which the gene of human tissue factor is implanted to an experimental animal such as a mouse and then growing the cell, thereby persistently supplying human tissue factor to the experimental animal. This animal model is useful for research and development of therapeutic agents for diseases having a persistent hypercoagulable state. Also provided are preventive or therapeutic agents for diseases having a persistent hypercoagulable state, a hypercoagulable state resulting from infections, venous thrombosis, arterial thrombosis, and diseases resulting from the hypertrophy of vascular media, the agent comprising an antibody against human tissue factor (human TF) as an active ingredient. | 03-22-2012 |
20120079612 | Dry eye animal model - A first embodiment is a dry eyed animal model method by peri or post-menopausal estrogen-treated rats have decreased tear production wherein the menopausal rat may be produced by ovariectomy Chronic estrogen exposure can decrease tear production in rats receiving a nine month course of estrogen versus placebo treatment after ovariectomy. The aged, chronically estrogen-treated female rats can provide a suitable model for the study of KCS and its treatment. | 03-29-2012 |
20120110684 | Method for Diagnosing or Predicting a Non Syndromic Autosomal Recessive Optic Atrophy, or a Risk of a Non Syndromic Autosomal Recessive Optic Atrophy - The present invention relates to a method for diagnosing or predicting a non syndromic autosomal recessive optic atrophy, or a risk of a non syndromic autosomal recessive optic atrophy. | 05-03-2012 |
20120117671 | STEATOHEPATITIS-LIVER CANCER MODEL ANIMAL - Fatty liver was induced by administering agents for inducing organ inflammation to experimental animals to evoke insulin resistance and by rearing them with high-fat diets. As a result, steatohepatitis was successfully induced in the animals. The animals show pathological findings similar to those of humans. By using these model animals, substances for treating or preventing diseases can be efficiently screened and the efficacy of medicinal substances can be effectively evaluated. | 05-10-2012 |
20120124682 | DHX36 / RHAU KNOCKOUT MICE AS EXPERIMENTAL MODELS OF MUSCULAR DYSTROPHY - The present invention provides a genetically-modified non-human animal whose somatic and germ cells contain a gene encoding an altered form of an DHX36 gene, the altered DHX36 haviang been targeted to replace a wild-type DHX36 gene into the animal or an ancestor of the animal at an embyonic stage using embryonic stem cells. An ideal use of the genetically-modified non-human animal of the invention is the use as an experimental model for muscular dystrophy, e.g. spinal muscular atrophy, to identify e.g. new treatments for muscular dystrophy and or study its pathogenesis. | 05-17-2012 |
20120144509 | NOVEL STRAINS OF HELICOBACTER PYLORI AND USES THEREOF - The present invention relates to strains of | 06-07-2012 |
20120151612 | NON-SURGICAL APPROACH TO PREVENT AND CORRECT CRANIOFACIAL MALFORMATIONS DURING DEVELOPMENT - The present invention discloses a novel TGF-β signaling mechanism implicated in craniofacial malformation as well as methods and compositions for treating craniofacial malformation utilizing knowledge of the mechanism. Methods of the invention generally comprises administering an effective amount of a TGF-β inhibitor to a subject in need of the treatment. Also disclosed are methods for treating craniofacial malformation by administering Tgf-β, Tgf-βRIII, p38 MAPK inhibitor or neutralizing antibodies to a subject. Also disclosed is a diagnostic method for diagnosing patients at risk of developing craniofacial malformation by determining the level of Tgf-β2 and ectopic p38 MAPK activation. Compounds useful for treating craniofacial malformation may also be discovered by using animal models of the present invention. | 06-14-2012 |
20120159658 | EXTRACELLULAR VESICLES DERIVED FROM GRAM-POSITIVE BACTERIA, AND USE THEREOF - The present application relates to extracellular vesicles (EVs) derived from gram-positive bacteria. In detail, the present application provides animal models of disease using extracellular vesicles derived from gram-positive bacteria, provides a method for screening an active candidate substance which is capable of preventing or treating diseases through the animal models of disease, provides vaccines for preventing or treating diseases caused by extracellular vesicles derived from gram-positive bacteria, and provides a method for diagnosing the causative factors of diseases caused by gram-positive bacteria using extracellular vesicles. | 06-21-2012 |
20120167237 | ANIMAL MODELS AND THERAPEUTIC MOLECULES - The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods. | 06-28-2012 |
20120180148 | TRANSGENIC MOUSE MODEL FOR DEVELOPING ENZYME REPLACEMENT THERAPY FOR IDURONATE-2-SULFATASE DEFICIENCY SYNDROME - The present invention relates to a transgenic mouse model for developing enzyme replacement therapy for iduronate-2-sulfatase deficiency syndrome, for example, Hunter syndrome. More specifically, the present invention relates to a transgenic mouse to be used for developing enzyme replacement therapy for iduronate-2-sulfatase, wherein the immune response against injected enzyme, such as, recombinant iduronate-2-sulfatase has been minimized in transgenic mouse model in the course of treating in vivo iduronate-2-sulfatase replacement. | 07-12-2012 |
20120180149 | DOUBLE MUTANT MOUSE AND CELL LINES - A mutant transgenic mouse and cell line derived from the mouse are disclosed. The mutant transgenic mouse was developed from a cross between a mutant mouse which carries mutant genes that express a phenotype similar to human Hermansky-Pudlak Syndrome, and a mouse strain containing a transgene encoding a temperature sensitive protein that is inactive at physiological temperatures. The resulting mutant mouse is characterized by the presence of the HPS mutations as well as the transgene. The mutant mouse and cell lines derived from the lung tissue of the mouse are useful models for lung pathology associated with human HPS, lung fibrosis and inflammation. Methods and assays utilizing the cell lines also are disclosed. | 07-12-2012 |
20120192295 | COMPOSITION COMPRISING EXTRACELLULAR MEMBRANE VESICLES DERIVED FROM INDOOR AIR, AND USE THEREOF - The present application relates to a composition comprising extracellular membrane vesicles derived from indoor air. In addition, the present application provides a method for diagnosing, preventing and/or treating an inflammatory respiratory disease, lung cancer and the like using the extracellular membrane vesicles. In detail, the present application involves injecting extracellular membrane vesicles present in indoor air into an animal in order to prepare an animal respiratory disease model, and enables the search and/or discovery of drug candidates for preventing or treating respiratory diseases using the animal model. The present application provides a vaccine for preventing and/or treating respiratory diseases, to a method for diagnosing substances causing respiratory diseases, and to a method for inhibiting the activities of extracellular membrane vesicles in indoor air or removing the extracellular membrane vesicles from indoor air so as to prevent the occurrence and exacerbation of respiratory diseases. | 07-26-2012 |
20120198576 | METHODS FOR MAKING EMBRYONIC CELLS, EMBRYOS, AND ANIMALS SENSITIZED TO STRESS - Embodiments of the invention are based upon the discovery that exposure of cleavage-stage embryos to a stress inducer, e.g. heat shock or chemical, renders the exposed embryos more sensitive to a secondary treatment with a stress inducer, e.g. heat shock or chemical inducer. Accordingly, the present invention is directed to methods for making embryos, embryonic cells arising from them, and animals and plants that are sensitized to stress, e.g. physiologic or chemical stressors. Methods of screening for inducers and inhibitors of stress using, as test model systems, embryonic cells, embryos, animals, and plants that are sensitized to stress are also disclosed. | 08-02-2012 |
20120198577 | Method of Isolating Human Neuroepithelial Precursor Cells from Human Fetal Tissue - A method for isolating human neuroepithelial precursor cells from human fetal tissue by culturing the human fetal cells in fibroblast growth factor and chick embryo extract and immunodepleting from the cultured human fetal cells any cells expressing A2B5, NG2 and eNCAM is provided. In addition, methods for transplanting these cells into an animal are provided. Animals models transplanted with these human neuroepithelial precursor cells and methods for monitoring survival, proliferation, differentiation and migration of the cells in the animal model via detection of human specific markers are also provided. | 08-02-2012 |
20120216303 | NOVEL THERAPEUTIC USES OF HUMAN FORMYL PEPTIDE RECEPTOR ANTAGONISTS - The invention features a transgenic mouse that expresses human formyl peptide receptor and methods for producing this mouse. The invention also features methods for the measurement of an inflammatory response, particularly that associated with cystic fibrosis. The methods of the invention also feature methods for determining whether a compound inhibits or prevents the recruitment of neutrophils. | 08-23-2012 |
20120216304 | HUMANIZED ANIMALS VIA TISSUE ENGINEERING AND USES THEREOF - Engineered human tissue constructs are provided that are suitable for use in making humanized animals for use in pharmaceutical development. Humanized animals having the constructs implanted in vivo are provided. Methods of making and using the tissue-engineered constructs and humanized animals are also provided. | 08-23-2012 |
20120222141 | ISLET1 (ISL1) AND HEARING LOSS - Described are methods and compositions for increasing islet-1 (Isl1) activity (e.g., biological activity) and or expression (e.g., transcription and/or translation) in a biological cell and or in a subject. | 08-30-2012 |
20120240245 | Methods and compositions for detecting and treating retinal diseases - The invention discloses multiple genes related to age-related macular degeneration (AMD) and/or phagocytosis by RPE cells of the eye, and methods and compositions for detecting and treating AMD and other retinal degenerative conditions based on these phagocytosis-related and/or AMD-related genes. Also provided are nonhuman transgenic animal models useful for testing therapeutic compounds and treatment protocols for AMD, and gene arrays including polymorphic variants of phagocytosis-related and/or AMD-related genes, useful for genetic screening of nucleic acid samples from subjects to obtain profiles of polymorphic variant sequences in a plurality of genes associated with AMD. Several preferred embodiments of the therapeutic compositions and animal models are based on target genes MT1-MMP and casein kinase 1 epsilon (CK1ε), phagocytosis-related genes found to be over-expressed in human donor eye samples from patients having both wet and dry forms of AMD. | 09-20-2012 |
20120255043 | MICRORNA AS A CANCER PROGRESSION PREDICTOR AND ITS USE FOR TREATING CANCER - The present invention is based on the findings that a novel function for miR142-3p in the regulation of Sox2, adenylyl cyclase 9 (AC9), and CD133 expressions, and consequently the overall stemness of recurrent GBM cells as well as CSCs, and that miR142-3p modulated tumor-initiating properties in recurrent GBM. The present invention consequently supports the development of novel miRNA-based strategies for brain tumor treatment. | 10-04-2012 |
20120255044 | URATE TRANSPORTER, AS WELL AS METHOD AND KIT FOR EVALUATING URATE TRANSPORT-RELATED DISEASE FACTOR AND INFLAMMATION-RELATED DISEASE FACTOR, AND TEST SAMPLE AND DRUG - A method and evaluation kit are provided, in which a high-capacity urate transporter is identified to assist in the early treatment and prevention of urate transport-related disease and inflammation-related disease. The method can include a step for detecting variations in genes that encode ABCG2 protein. When a subject has an SNP of V12M, R113X, Q126X, Q141K, F208S, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, and/or C608X, it can be concluded that the subject has a factor that is capable of inducing urate transport failure, or a state or disease attributable to that failure. When a subject has an SNP of V12M, it can be concluded that, unlike the other SNPs, there is a possibility that the subject does not possess such a factor because, although this variation itself does not lead to a change in urate transport capability, said variation is related to linkage disequilibrium with other SNPs. | 10-04-2012 |
20120266260 | DIAGNOSING AND TREATING IGA NEPHROPATHY - Provided are methods of diagnosing IgA nephropathy in a subject. Optionally, the methods comprise isolating an IgG from the subject and determining whether the IgG binds to a galactose-deficient IgA1. Optionally, the methods comprise providing a biological sample from the subject and detecting in the sample a mutation in a IGH gene, wherein the mutation is in a nucleotide sequence encoding a complementarity determining region 3 (CDR3) of a IGH variable region. Optionally, the methods comprise determining a level of IgG specific for a galactose-deficient IgA1 in the subject. Also provided are methods of treating or reducing the risk of developing IgA nephropathy in a subject. | 10-18-2012 |
20120266261 | NEUROVIRULENT STRAIN OF THE WEST NILE VIRUS AND USES THEREOF - Neuroinvasive and neurovirulent strain of the West Nile virus, named IS-98-ST1, nucleic acid molecules derived from its genome, proteins and peptides encoded by said nucleic acid molecules, and uses thereof. | 10-18-2012 |
20120266262 | METHODS AND COMPOSITIONS RELATING TO ZPA POLYPEPTIDES - The present invention provides ZPA polypeptides, antibodies, nucleic acid molecules, antagonists, agonists, potentiators and compositions relating to ZPA polypeptides, and methods of identifying, making and using the same, that are useful for treating and preventing diseases and for medical diagnosis and research. The present invention also provides model systems for the intrinsic apoptotic pathway. | 10-18-2012 |
20120272345 | DIAGNOSIS MARKER, DIAGNOSIS METHOD AND THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS, AND ANIMAL MODEL AND CELL MODEL DEVELOPING AMYOTROPHIC LATERAL SCLEROSIS - Provided are a diagnosis marker, a diagnosis method, and a therapeutic agent suitable for diagnosing and treating amyotrophic lateral sclerosis (ALS). Also provided are an animal model and a cell model suitable for developing a therapeutic agent and a treatment method for ALS. The diagnosis method for ALS includes: an isolation step in which a nucleic acid is isolated from a specimen taken from a subject; a detection step in which bases expressed in a human chromosome 10 optineurin (OPTN) gene region are detected from the isolated nucleic acid; and a determination step in which it is determined whether or not the detected bases are mutated. | 10-25-2012 |
20120278908 | METHOD FOR THE DIAGNOSIS/PROGNOSIS OF AGE-RELATED MACULAR DEGENERATION - The present invention relates to a method for diagnosing or predicting age related maculopathy or age-related macular degeneration, or a risk of age related maculopathy or age-related macular degeneration, in a subject, said method comprising detecting in a sample obtained from said subject at least one polymorphism in the SCARB1 gene, wherein the presence of said polymorphism is indicative of non age related maculopathy or age-related macular degeneration or of a risk of age related maculopathy or age-related macular degeneration. | 11-01-2012 |
20120291147 | GRAVITATIONAL FLUCTUATION STRESS LOADING METHOD, AIRCRAFT, AIRCRAFT-FLYING METHOD, METHOD FOR PROMOTING SEROTONIN-PRODUCING GENE EXPRESSION, SEROTONIN-PRODUCING METHOD, METHOD FOR STIMULATING CENTRAL NERVOUS SYSTEM, AND EFFICACY-MEASURING METHOD - A gravitational fluctuation stress loading method capable of causing a new acute stress reaction in a subject or a laboratory animal is provided. A gravitational fluctuation stress loading method including at least one first stress-loading step (S | 11-15-2012 |
20120311728 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ATHEROSCLEROSIS - The present invention relates to the prevention or treatment of atherosclerosis, in particular to a group X sPLA2 polypeptide for use in the treatment of atherosclerosis. | 12-06-2012 |
20120311729 | Immunomodulatory Methods and Systems for Treatment and/or Prevention of Atherosclerosis - Immunostimulatory methods and systems for treating or preventing atherosclerosis and/or a condition associated thereto in an individual. | 12-06-2012 |
20130019326 | Compositions, Kits, and Methods for Identification, Assessment, Prevention, and Therapy of Metabolic Disorders - The invention provides methods and compositions for selectively promoting anti-metabolic disorder activity over classical PPAR gamma activation through modulation of PPAR gamma phosphorylation (e.g., Ser-273 phosphorylation of murine peroxisome proliferator activated receptor gamma (PPAR gamma) 2 or a corresponding serine residue in a murine PPAR gamma 2 homolog, including a human). Also provided are methods for preventing, treating, or predictiving responsiveness of therapies for metabolic disorders in a subject through selective inhibition of such PPAR gamma phosphorylation. Further provided are methods for identifying compounds that are capable of modulating such PPAR gamma phosphorylation. | 01-17-2013 |
20130024957 | GENETICALLY MODIFIED MICE AND ENGRAFTMENT - A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mII2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/II2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., | 01-24-2013 |
20130031645 | METHOD FOR HEPATIC DIFFERENTIATION OF DEFINITIVE ENDODERM CELLS - The present invention relates to a method for obtaining a population of hepatic progenitor cells, said method comprising a step of culturing definitive endoderm cells with a culture medium stimulating hepatic specification. In a particular embodiment, such culture medium stimulating hepatic specification comprises a retinoic acid receptor (RAR) agonist, an FGF family growth factor and an inhibitor of the activin signaling pathway. | 01-31-2013 |
20130031646 | MODEL SYSTEM OF ACANTHAMOEBA KERATITIS SYNDROME AND METHOD FOR SELECTING A TREATMENT THEREOF - Methods for generating a feline model for ocular complications arising from amoeba infection are described. The invention further relates to screening methods for therapeutics for the treatment of ocular complications using the feline model referenced to above. | 01-31-2013 |
20130042330 | HUMANIZED M-CSF MICE - Genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein are provided. Also provided are genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein that have been engrafted with human cells such as human hematopoietic cells, and methods for making such engrafted mice. These mice find use in a number of applications, such as in modeling human immune disease and pathogen infection; in in vivo screens for agents that modulate hematopoietic cell development and/or activity, e.g. in a healthy or a diseased state; in in vivo screens for agents that are toxic to hematopoietic cells; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on hematopoietic cells; in in vivo screens of human hematopoietic cells from an individual to predict the responsiveness of an individual to a disease therapy, etc. | 02-14-2013 |
20130042331 | ANIMAL MODELS AND THERAPEUTIC MOLECULES - The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods. | 02-14-2013 |
20130042332 | Device and method for inducing brain injury in animal test subjects - An apparatus and method for inflicting brain injury on a laboratory animal that employs a platform for supporting the laboratory animal. The platform defines an opening for positioning the head of the laboratory animal over the opening. A projectile is launched from a projectile launching device orientated below the opening of the platform. The projectile launching device has a means for propelling the projectile directly at and/or through the opening of said platform, thereby inflicting brain injury on the animal via either a pressure wave or concussive impact of the projectile. Without helmet, direct impact of the projectile results in severe traumatic brain injury. Use of helmet protects animals from skull fracture, subdural hematoma, intracerebral hemorrhage and contusion yet produces mild concussion-like pathology. | 02-14-2013 |
20130047273 | Genetically altered animal specimen and related methods - A genetically altered animal specimen is provided by a process comprising: identifying a gene that is desired to be altered, disrupting the gene in a gene carrier to thereby create a new DNA fragment; inserting the new DNA fragment into an embryonic cell, injecting the embryonic cell which exhibits the desired genetic alteration into an embryo, inserting the embryo into a uterus of a carrier whereby the carrier's offspring shall exhibit the desired genetic alteration, and the offspring is the genetically altered animal specimen, in this case the neurocalcin δ gene knockout mouse model. | 02-21-2013 |
20130061339 | METHOD OF DIAGNOSING TRICHOTILLOMANIA AND SIMILAR DISORDERS IN HUMANS AND RODENTS - The present disclosure provides a method of diagnosing neurological disorders including for example, impulse control disorders, such as barbering and trichotillomania using biomarkers such as reductive capacity of urine and 8-OH-dG concentration. Still other disorders that can be diagnosed based on the measurements of makers for oxidative stress include autism and Parkinson's disease. | 03-07-2013 |
20130074199 | Compositions and Methods for Brown Fat Induction and Activity Using FNDC5 - The invention provides compositions and methods for brown fat induction and activity through modulation of Fndc5 activity and/or expression. Also provided are methods for preventing or treating metabolic disorders in a subject through modulation of Fndc5 activity and/or expression. Further provided are methods for identifying compounds that are capable of modulating Fndc5 activity and/or expression. | 03-21-2013 |
20130081148 | NRIP KNOCKOUT MICE AND USES THEREOF - The present invention directs to a transgenic NRIP knockout mouse, the genome of which is manipulated to comprise a disruption of a nuclear receptor interaction protein (NRIP) gene, wherein the NRIP gene is disrupted by deletion of exon 2, the mouse exhibits a phenotype comprising abnormal muscular function. The present invention also directs to a method for making a transgenic NRIP knockout mouse whose genome comprises a homozygous disruption of the NRIP gene, the mouse exhibits abnormal muscular function. | 03-28-2013 |
20130086703 | PERIODONTAL-DISEASE-SPECIFIC PEPTIDE, AND TREATMENT AND DIAGNOSIS OF PERIODONTAL DISEASE USING SAME - The present invention provides an inhibitor of an autoimmune response to a periodontal bacterial enzymatic degradation product of keratin in gingival epithelium in a mammal having a periodontal bacterium in the oral cavity, containing a substance having affinity to the keratin or a degradation product thereof and/or a substance having affinity to an autoantibody to the degradation product, an agent for the prophylaxis and/or treatment of a periodontal disease and/or a complication thereof; a RANKL expression inhibitor containing a substance having affinity to the keratin or a degradation product thereof; and a method of diagnosing a periodontal disease including detecting the keratin or a degradation product thereof and/or an autoantibody thereto. | 04-04-2013 |
20130086704 | PHARMACEUTICAL COMPOSITION UTILIZING PANCREATIC BETA CELL PROLIFERATION FACTOR - Disclosed are a pharmaceutical composition, a screening method, and the like which use UDP-glucose glycoprotein glycosyl transferase 1 (UGGT1) or a gene encoding the same. UGGT1 has an extremely high proliferative activity compared to known pancreatic β-cell proliferation factors; thus, UGGT1 can act as a useful therapeutic agent for diabetes without any modification and is also useful as a target substance for the development of a new therapeutic agent for diabetes. | 04-04-2013 |
20130097717 | COMPOSITIONS AND METHODS FOR RE-PROGRAMMING CELLS WITHOUT GENETIC MODIFICATION FOR TREATMENT OF CARDIOVASCULAR DISEASES - The present inventions are directed to compositions and methods regarding the reprogramming of other cells (such as fibroblast cells) into cardiomyocytes without introducing exogenous genes to the samples. In particular, the present inventions are directed to transducible materials that are capable of transducing into the biological samples but are not genes or causing genetic modifications. The present inventions also are directed to methods of reprogramming the path of biological samples or treating diseases using the tranducible compositions thereof. | 04-18-2013 |
20130111612 | PRIMATE MODEL FROM THE FAMILY CERCOPITHECIDAE INFECTED BY A HBV STRAIN OF HUMAN GENOTYPE | 05-02-2013 |
20130145485 | METHODS AND COMPOSITIONS FOR ALTERATION OF A CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE - Nucleases and methods of using these nucleases for alteration of a CFTR gene and generation of cells and animal models. | 06-06-2013 |
20130191933 | METHODS OF TREATING PAIN AND MORPHINE TOLERANCE VIA MODULATION OF HEDGEHOG SIGNALLING PATHWAY - Described herein are methods of treating nociception by administering to a subject in need thereof a therapeutic amount of one or more compounds which modulate the Hedgehog signaling pathway. | 07-25-2013 |
20130191934 | TREATMENT OF SYMPTOMS ASSOCIATED WITH MENOPAUSE - A method for treating symptoms associated with a dramatic reduction in reproductive hormone levels is provided, particularly in menopausal women and breast cancer survivors undergoing aromatase inhibitor therapy. The method comprises administered to a subject an inhibitor of orexin activity in an amount sufficient to reduce or decrease onset, progression, severity, frequency, duration or probability of one or more such symptoms. A method of detecting compounds having activity for relieving menopausal symptoms is also provided. | 07-25-2013 |
20130198875 | RNA SEQUENCE-SPECIFIC MEDIATORS OF RNA INTERFERENCE - The present invention relates to a | 08-01-2013 |
20130212720 | BIOMARKERS ASSOCIATED WITH AUTOIMMUNE DISEASES OF THE LUNG - The present disclosure is generally related to pulmonary autoantigens. The disclosure provides methods and kits for assessing whether a subject has or is predisposed to interstitial lung disease. Additionally the present disclosure provides methods of treatment and animal models of interstitial lung disease. | 08-15-2013 |
20130219530 | Leishmania Challenge Model - The present invention provides a method for effectively and reproducibly infecting canines with | 08-22-2013 |
20130227715 | USE OF ENDONUCLEASES FOR INSERTING TRANSGENES INTO SAFE HARBOR LOCI - The present invention concerns the endonucleases capable of cleaving a target sequence located in a “safe harbor loci”, i.e. a loci allowing safe expression of a transgene. The present invention further concerns the use of such endonucleases for inserting transgenes into a cell, tissue or individual. | 08-29-2013 |
20130227716 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION - Coronatine has been found to enhance binding of the JAZ1 degron to the | 08-29-2013 |
20130227717 | HDAC INHIBITORS TO TREAT CHARCOT-MARIE-TOOTH DISEASE - The present application relates to diseases in the peripheral nervous system, particularly hereditary neuropathies, most particularly, Charcot-Marie-Tooth (CMT) disease. It is shown that this disease is associated with decreased acetylated tubulin levels, which can be overcome by inhibition of histone deacetylases (HDACs). Using HDAC inhibitors, it is shown herein that the symptoms of the CMT phenotype can be overcome both in vitro and in vivo. Also provided herein are two different mouse models of CMT disease. | 08-29-2013 |
20130254907 | HUMANIZED TRANSGENIC ANIMAL - This present invention relates to transgenic animals useful to study human diseases. Specifically, the invention relates to transgenic animals expressing at least two human proteins (optionally in replacement of the counterpart proteins in the animal) whereas a first human protein interacts with a second human protein. The transgenic animals can then be used for evaluating drugs or building disease models that are related to the expressed human proteins in the animals. The animals and methods disclosed herein reduce the possibility identifying a false-positive compound—the compound that show an effect in a naturally-occurring, non-transgenic animal but may not necessarily work or be therapeutic in human, since the compound may only interrupt the interaction between two animal proteins not necessarily two related human proteins. Also, the animals and methods disclosed herein reduce the possibility of identifying a false-negative compound—a compound that does not work or have any effect in a naturally-occurring, non-transgenic animal but may have therapeutic effect in human, since the compound may only interrupt the interaction between at least two relevant human proteins not necessarily two related animal proteins. | 09-26-2013 |
20130276154 | Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank - Methods for producing stem cell banks, preferably human, which optionally may be transgenic, e.g., comprised of homozygous MHC allele cell lines are provided. These cells are produced preferably from parthenogenic, IVF, or same-species or cross-species nuclear transfer embryos or by dedifferentiation of somatic cells by cytoplasm transfer. Methods for using these stem cell banks for producing stem and differentiated cells for therapy, especially acute therapies, and for screening for drugs for disease treatment are also provided. | 10-17-2013 |
20130305397 | GENE CAPABLE OF REGULATING OBESITY/INSULIN SENSITIVITY - This invention relates to a cell comprising a reporter gene under control of an ARIA gene promoter, the cell being used for searching for an agent for prevention or treatment of diseases attributed to reduced insulin sensitivity, for searching for an obesity-controlling substance, or for searching for an obesity-inducing substance. | 11-14-2013 |
20130318644 | METHODS FOR TREATING DISORDERS THAT INVOLVE IMMUNOGLOBULIN A - Provided herein are FDC-SP polypeptides and methods of using such polypeptides. Methods include, but are not limited to, altering IgA concentration in a subject, treating a subject having signs of a disorder that includes excessive IgA production, identifying a compound that decreases the concentration of IgA in an animal, and identifying a compound that treats a condition associated with increased levels of IgA. Also provided herein is an animal that has decreased expression of an endogenous FDC-SP coding sequence. The animal may develop pathophysiological features of IgA nephropathy, and/or may display increased IgA in serum, saliva, bronchoalveolar lavage fluid, or a combination thereof; increased IgA expressing B lymphocytes in circulation, lymphoid tissue, or a combination thereof; or increased IgA production in vitro by isolated B lymphocytes | 11-28-2013 |
20130333058 | Pluripotent Cells From Rat and Other Species - Pluripotent cells are derived and maintained in a self-renewing state in serum-free culture medium comprising a MEK inhibitor, a GSK3 inhibitor and an antagonist of an FGF receptor. | 12-12-2013 |
20130340101 | Novel Homeobox Gene - An isolated nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO: 1. | 12-19-2013 |
20130347136 | Compositions and Methods for Characterizing and Treating Muscular Dystrophy - Compositions and methods for identifying new treatments for Facioscapulohumeral muscular dystrophy (FSHD), and uses thereof. | 12-26-2013 |
20130347137 | Stabilized Step Function Opsin Proteins and Methods of Using the Same - Provided herein are compositions comprising non-human animals comprising neurons expressing stabilized step function opsin proteins on neural plasma membranes and methods of using the same to selectively depolarize neurons residing in microcircuits of the pre-frontal cortex to affect one or more social behaviors, communications, and/or conditioned behaviors in the non-human animal. | 12-26-2013 |
20140041065 | Animal Model of Central Neuropathic Pain and Methods of Making and Using the Same - The present disclosure describes an animal model of central neuropathic pain relevant to spinal cord injury, as well as methods of using the model to screen for therapeutic agents and to test existing therapies. | 02-06-2014 |
20140068794 | R2R1/2 In Diagnosis and Therapy - The present invention stems from the finding that two genes designated R2R | 03-06-2014 |
20140082758 | Control and Characterization of Psychotic States - Provided herein are methods of inducing psychosis in animals using light-responsive opsins and methods of identifying or screening compounds that may be useful in treating psychosis. | 03-20-2014 |
20140096273 | MOUSE FOR PREDICTING A BEHAVIOR OF DRUGS IN HUMANS - The present invention is directed to the production, breeding and use of transgenic non-human animals such as mice in which specific genes, such as serum albumin, or portions of genes have been replaced by homologs from another animal, such as a human, to make the physiology of the animals so modified more like that of the other animal with respect to drug pharmacokinetics and metabolism. The invention also extends to the use of the genetically modified non-human animals of the invention for pharmacological and/or toxicological studies. | 04-03-2014 |
20140123329 | hnRNP A1 KNOCKOUT ANIMAL MODEL AND USE THEREOF - A nucleic acid construct comprising a genetic engineered heterogeneous nuclear ribonucleoprotein (hnRNP) A1 gene is provided. A transgenic mouse in which the expression of hnRNP A1 gene has been disrupted is also provided. The mouse is useful for studying the role of hnRNP A1 gene in normal and disease states of a developmental disorder and muscular diseases. Therefore, a method of screening a compound for potential use in prevention and/or treatment of developmental disorder and muscular diseases is further provided. | 05-01-2014 |
20140130191 | METHODS FOR TREATING IMMUNE-MEDIATED DISEASES OF THE NERVOUS SYSTEM ADMINISTERING A COMPOUND COMPRISING AGENTS THAT INHIBIT PROKINETICIN RECEPTORS ACTIVITY - The invention relates to a compound comprising non-peptide prokineticin receptors antagonists and agents that modulate or inhibit the activity of prokineticin receptors for use in the treatment of immune-mediated diseases of the central nervous system, peripheral nervous system and neuromuscular junctions. | 05-08-2014 |
20140143897 | EPHA4 IS A DISEASE MODIFIER IN MOTOR NEURON DISEASE - The present application relates to the field of motor neuron diseases, most particularly to amyotrophic lateral sclerosis and spinomuscular atrophy. Provided herein are strategies to improve symptoms and increase survival in patients with these axonopathies by inhibiting signaling mediated by the EphA4 ephrin receptor. | 05-22-2014 |
20140165219 | MUTANT SODIUM CHANNEL Nav1.7 AND METHODS RELATED THERETO - Described are mutant Na | 06-12-2014 |
20140182003 | ANIMAL MODELS AND THERAPEUTIC MOLECULES - The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods. | 06-26-2014 |
20140182004 | MOUSE MODEL OF RETINAL DEGENERATION - The invention is directed to a method of producing a non-human mammal having one or more pathological characteristics of retinal degeneration and/or age-related macular degeneration. In particular, the invention provides a method of producing a non-human mammal having age-related macular degeneration (AMD). The invention is also directed to non-human animals produced by the methods described herein. Methods of identifying an agent for use in inhibiting one or more pathological characteristics of retinal degeneration and/or AMD is also encompassed by the invention. Also provided is a method of treating AMD in an individual in need thereof comprising, administering to the individual an agent identified herein. | 06-26-2014 |
20140223589 | ANIMAL MODELS OF DUCHENNE MUSCULAR DYSTROPHY - The present invention provides transgenic, large non-human animal models of Duchenne muscular dystrophy, Becker muscular dystrophy, and DMD-associated dilated cardiomyopathy, as well as methods of using such animal models in the identification and characterization of therapies for Duchenne muscular dystrophy, Becker muscular dystrophy, and DMD-associated dilated cardiomyopathy. | 08-07-2014 |
20140250542 | MITOCHONDRIAL-NUCLEAR EXCHANGED CELLS, TISSUES, ORGANS AND ANIMALS - Provided herein are mitochondrial-nuclear exchanged cells and animals comprising mitochondrial DNA (mtDNA) from one subject and nuclear DNA (nDNA) from a different subject. Methods for producing a mitochondrial-nuclear exchanged animal and animals made by the methods are provided. Also provided are methods of screening for agents useful for treating a disease or disorder using mitochondrial-nuclear exchanged animals or cells, tissues or organs thereof. | 09-04-2014 |
20140283153 | TRANSGENIC ANIMALS AND METHODS OF USE - This invention relates to transgenic vertebrates, and more specifically to transgenic vertebrates for the development of human therapeutics. | 09-18-2014 |
20140289878 | METHOD FOR PRODUCING MODEL ANIMAL, AND MODEL ANIMAL - A method for producing a model animal which has a desired lifetime, and in which a predetermined biological reaction can be induced, and a model animal are provided. The present invention produces a first individual in which a gene of interest is heterozygously deficient using a first ES cell from a non-human mammalian animal. Meanwhile, a fragment containing a homologous gene that has homology to the gene of interest is made, a second ES cell constituted so that a predetermined region on X chromosome of the animal can be substituted is used, and the fragment is introduced into the second ES cell to generate a substituted ES cell in which the predetermined region has been substituted with the fragment. A second individual is produced using the substituted ES cell. The first individual and the second individual are mated with each other to produce a model animal. | 09-25-2014 |
20140298496 | PHENOCOPY MODEL OF DISEASE - Methods and compositions for generating nonhuman disease models through splicing modulation. | 10-02-2014 |
20140298497 | HUMAN MAST CELL LINES, PREPARATION AND USES - The present invention relates to a human mast cell line corresponding to deposit number CNCM I-4551 and also to the lines derived therefrom, in particular the derived lines corresponding respectively to deposit numbers CNCM I-4552 and CNCM I-4553, and to the uses thereof, in particular for screening for compounds of therapeutic interest. | 10-02-2014 |
20140310828 | TARGETED MODIFICATION OF RAT GENOME - Compositions and methods are provided for modifying a rat genomic locus of interest using a large targeting vector (LTVEC) comprising various endogenous or exogenous nucleic acid sequences as described herein. Compositions and methods for generating a genetically modified rat comprising one or more targeted genetic modifications in their germline are also provided. Compositions and methods are provided which comprise a genetically modified rat or rat cell comprising a targeted genetic modification in the rat interleukin-2 receptor gamma locus, the rat ApoE locus, the rat Rag2 locus, the rat Rag1 locus and/or the rat Rag2/Rag1 locus. The various methods and compositions provided herein allows for these modified loci to be transmitted through the germline. | 10-16-2014 |
20140351964 | TRANSGENIC MOUSE MODEL FOR DEVELOPING ENZYME REPLACEMENT THERAPY FOR IDURONATE-2-SULFATASE DEFICIENCY SYNDROME - The present invention relates to a transgenic mouse model for developing enzyme replacement therapy for iduronate-2-sulfatase deficiency syndrome, for example, Hunter syndrome. More specifically, the present invention relates to a transgenic mouse to be used for developing enzyme replacement therapy for iduronate-2-sulfatase, wherein the immune response against injected enzyme, such as, recombinant iduronate-2-sulfatase has been minimized in transgenic mouse model in the course of treating in vivo iduronate-2-sulfatase replacement. | 11-27-2014 |
20140373187 | FUMARYLACETOACETATE HYDROLASE (FAH)-DEFICIENT AND IMMUNODEFICIENT RATS AND USES THEREOF - Described herein are rats with a hepatic deficiency comprising decreased function, activity, or expression of an enzyme in the tyrosine catabolic pathway (such as fumarylacetoacetate hydrolase), and methods of using the same for in vivo engraftment and expansion of heterologous hepatocytes, such as human hepatocytes, analysis of human liver disease, and analysis of xenobiotics. Also disclosed is the use of immunodeficient rats for the engraftment and expansion of heterologous hepatocytes. | 12-18-2014 |
20150020221 | Compositions and Methods for the Modulation of DNA Damage Responses Using BAL1 and BBAP - The invention provides methods and compositions for enhancing the efficacy of cancer therapies through modulation of BAL1 and/or BBAP. Also provided are methods for predicting the efficacy of cancer therapies or treating cancer in a subject through modulation of BAL1 and/or BBAP. Further provided are methods for identifying compounds that are capable of modulating BAL1-BBAP complexes. | 01-15-2015 |
20150026833 | Mito-Ob: A Transgenic Mouse Model for Obesity - An obese mouse model was developed by overexpressing the mitochondrial protein prohibitin (PHB) in white adipose tissue (WAT) specific manner driven by adipocyte protein 2 (aP2) promoter. These mice begin to develop obesity as a result of mitochondrial remodeling (upregulation of mitochondrial biogenesis and function) in WAT. | 01-22-2015 |
20150033370 | MODEL AND METHOD FOR A TRANSGENIC BOVIDAE EXPRESSING CARDIAC FIBROSIS AND ASSOCIATED PATHOLOGY - Herein provided are a model and method for a transgenic a bovidae having an TGF-β1 gene inserted into the bovidae genome and capable of expressing higher than normal levels of TGF-β1 in cardiac muscle. | 01-29-2015 |
20150047062 | lincRNA-DEFICIENT NON-HUMAN ANIMALS - Genetically modified non-human animals are provided that exhibit a functional lack of one or more lncRNAs. Methods and compositions for disrupting, deleting, and/or replacing lncRNA-encoding sequences are provided. Genetically modified mice that age prematurely are provided. Also provided are cells, tissues and embryos that are genetically modified to comprise a loss-of-function of one or more lncRNAs. | 02-12-2015 |
20150052625 | HUMANIZED MOUSE - The present invention provides embryonic stem cells obtainable from an embryo of an immunodeficient mouse which is deficient in both Rag2 and Jak3 genes by culture in the presence of a GSK3 inhibitor and an MEK inhibitor, as well as a transgenic mouse, which is created with the use of these embryonic stem cells. | 02-19-2015 |
20150074836 | MUTATIONS OF THE PARKIN GENE, COMPOSITIONS, METHODS AND USES - The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes. | 03-12-2015 |
20150082467 | PHARMACEUTICAL COMPOSITION FOR VIRAL TREATMENT, AND METHOD FOR SCREENING ANTIVIRAL AGENT - The present invention relates to; a pharmaceutical compostion capable of enhancing immunity against viruses by specifically decreasing the expression of the OASL1 protein; and a method for screening for a material capable of being used as an antiviral agent by comparing the amount of expression of the OASL1 protein. | 03-19-2015 |
20150082468 | INVERSE PATTERNING PROCESS FOR THREE-DIMENSIONAL MULTI-COMPARTMENTAL MICRO-ORGANIZATION OF MULTIPLE CELL TYPES - The invention features an “inverse patterning” or “Intaglio-Void/Embed-Relief Topographic (In VERT) molding” manufacturing process for generating high-resolution three-dimensional (3D) multi-cellular microstructures in distinct cellular compartments of a single hydrogel. The platform has general utility in the development of engineered tissues for human therapies, drug testing, and disease models. Additionally, the platform can serve as a model system for studying 3D cell-cell interactions in fields as diverse as stem cell biology to the development of cancer therapeutics. | 03-19-2015 |
20150096063 | MOUSE ARTIFICIAL CHROMOSOME VECTOR - Disclosed is a mouse artificial chromosome vector, comprising: a natural centromere derived from a mouse chromosome; a mouse-chromosome-derived long-arm fragment formed by deleting a long-arm distal region at a mouse chromosome long-arm site proximal to the centromere; and a telomere sequence, wherein the vector is stably retained in a cell and/or tissue of a mammal. In addition, disclosed are cells or non-human animals comprising the vector, and use of the cells or non-human animals. | 04-02-2015 |
20150106960 | METHOD FOR DIAGNOSING A SKELETAL CILIOPATHY - The present invention relates to a method for diagnosing a skeletal ciliopathy. | 04-16-2015 |
20150106961 | Humanized IL-15 Animals - Genetically modified non-human animals comprising a humanized interleukin-15 (IL-15) gene. Cells, embryos, and non-human animals comprising a human IL-15 gene. Rodents that express humanized or human IL-15 protein. | 04-16-2015 |
20150113672 | Composition and Methods for Producing Reconstituted Skin - Compositions and methods for producing reconstituted human skin and/or hair follicles in situ are provided. The method for producing the skin is unique in that tissue culture expanded cells including multipotent cells such as neonatal cells as well as cultured epidermal and dermal cells are immediately placed on a substrate such as a membrane and then the membrane with adherent cells is placed on a skin wound. Examples demonstrate formation of hair follicles in situ. | 04-23-2015 |
20150113673 | CD81 AND OCLN DOUBLE TRANSGENIC MOUSE AND ITS CONSTRUCTION METHODS - The present invention provides a CD81 and OCLN double transgenic mouse and its construction method and use. The double transgenic mouse can be used to constitute acute and chronic HCV infection in a mouse model. | 04-23-2015 |
20150128299 | NORMALIZATION OF THE ENTEROHEPATIC CIRCULATION IN ANIMALS WITH A CHIMERIC HUMANIZED LIVER - Methods of normalizing bile acid production in a mouse engrafted with human hepatocytes by the administration of human FGF19 are disclosed. Also disclosed is a transgenic host animal, such as a mouse, that expresses human FGF19 that has normalized bile acid production when engrafted with human hepatocytes. | 05-07-2015 |
20150143556 | Mutant Alpha-Synuclein, and Methods Using Same - The present invention relates to a mutant human alpha-synuclein with increased toxicity compared to wild-type alpha-synuclein, or a homologue thereof, wherein the mutant alpha-synuclein or homologue thereof comprises at least one amino acid substitution selected from the group consisting of a substitution at the alanine at position 56 (A56), at the alanine at position 76 (A76), at the methionine at position 127 (M127) and/or at the valine at position 118 (V118), as defined in the claims. Further, the invention relates to a polynucleotide encoding the mutant alpha-synuclein or homologue thereof, or an expression vector comprising said polynucleotide, a cell comprising the polynucleotide or expression vector, as defined in the claims. Also, a non-human animal comprising the cell of the invention is provided, as defined in the claims. Finally, the invention provides methods for identifying a substance that prevents or reduces toxicity of alpha-synuclein, as defined in the claims. | 05-21-2015 |
20150143557 | COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS - It was found that bacteria belonging to the genus | 05-21-2015 |
20150143558 | NON-HUMAN ANIMALS HAVING A HUMANIZED B-CELL ACTIVATING FACTOR GENE - Non-human animals, cells, methods and compositions for making and using the same are provided, wherein the non-human animals and cells comprise a humanized B-cell activating factor gene. Non-human animals and cells that express a human or humanized B-cell activating factor protein from an endogenous B-cell activating factor locus are described. | 05-21-2015 |
20150143559 | NON-HUMAN ANIMALS HAVING A HUMANIZED A PROLIFERATION-INDUCING LIGAND GENE - Non-human animals, cells, methods and compositions for making and using the same are provided, wherein the non-human animals and cells comprise a humanized a proliferation-inducing ligand gene. Non-human animals and cells that express a human or humanized a proliferation-inducing ligand protein from an endogenous a proliferation-inducing ligand locus are described. | 05-21-2015 |
20150143560 | ANIMAL MODEL FOR EPILEPSY AND METHOD FOR PRODUCING THE SAME - The present invention relates to a technique for inducing epilepsy and a non-human animal model of epilepsy. More particularly, the present invention relates to a method for inducing epilepsy in an animal, a non-human animal model of epilepsy, and a method for manufacturing the same. | 05-21-2015 |
20150143561 | NON-HUMAN ANIMALS HAVING A HUMANIZED B-CELL ACTIVATING FACTOR GENE - Non-human animals, cells, methods and compositions for making and using the same are provided, wherein the non-human animals and cells comprise a humanized B-cell activating factor gene. Non-human animals and cells that express a human or humanized B-cell activating factor protein from an endogenous B-cell activating factor locus are described. | 05-21-2015 |
20150143562 | NON-HUMAN ANIMALS HAVING A HUMANIZED A PROLIFERATION-INDUCING LIGAND GENE - Non-human animals, cells, methods and compositions for making and using the same are provided, wherein the non-human animals and cells comprise a humanized a proliferation-inducing ligand gene. Non-human animals and cells that express a human or humanized a proliferation-inducing ligand protein from an endogenous a proliferation-inducing ligand locus are described. | 05-21-2015 |
20150296756 | Animal Models of Neurological Disorders - The present invention relates to the field of neurological disorders and more particularly to the field of neuropsychiatric disorders. The invention provides non-human, transgenic animal models for brain disorders such as schizophrenia, bipolar disorders, compulsive disorders, addictive disorders and the like. The animals also have applications in the field of GABA neurotransmission and other disorders in which GABA-dependent gene regulation has a role. | 10-22-2015 |
20150296758 | HUMANIZED TRANSGENIC SINGLE NUCLEOTIDE POLYMORPHISM ANIMAL SYSTEMS - The present invention relates to the field of transgenic animals. More specifically, the present invention provides methods and composition related to humanized transgenic single polymorphism non-human animal systems. In one embodiment, a system comprises (a) a transgenic non-human animal comprising a transgene encoding a wildtype human protein, wherein the protein is biologically active in the animal; and (b) at least one transgenic non-human animal comprising a transgene encoding a variant human protein, wherein the protein is biologically active in the animal and wherein the variant comprises one or more single nucleotide polymorphisms (SNPs). | 10-22-2015 |
20150320805 | COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS - It was found that bacteria belonging to the genus | 11-12-2015 |
20150327524 | GENETICALLY MODIFIED NON-HUMAN ANIMALS EXPRESSING HUMAN EPO - Genetically modified non-human animals expressing human EPO from the animal genome are provided. Also provided are methods for making non-human animals expressing human EPO from the non-human animal genome, and methods for using non-human animals expressing human EPO from the non-human animal genome. These animals and methods find many uses in the art, including, for example, in modeling human erythropoiesis and erythrocyte function; in modeling human pathogen infection of erythrocytes; in in vivo screens for agents that modulate erythropoiesis and/or erythrocyte function, e.g. in a healthy or a diseased state; in in vivo screens for agents that are toxic to erythrocytes or erythrocyte progenitors; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on erythrocytes or erythrocyte progenitors; in in vivo screens of erythrocytes or erythrocyte progenitors from an individual to predict the responsiveness of an individual to a disease therapy. | 11-19-2015 |
20150328339 | HUMAN GLIAL CHIMERIC MODEL FOR DRUG CANDIDATE ASSESSMENT IN HUMAN GLIOTROPHIC VIRAL INFECTIONS AND PROGRESSIVE MULTIFOCAL ENCEPHALOPATHY - The present invention is directed to a method of assessing in vivo human glial cell response to pathogenic infection that involves providing a non-human mammal either with at least 30% of its glial cells in its corpus callosum being human glial cells and/or with at least 5% of its glial cells its brain and brain stem white matter being human glial cells, subjecting the non-human mammal to pathogenic infection and assessing the in vivo human glial cell response to pathogenic infection. A method of identifying therapeutic agents for the pathogenic infection as well as forms of the non-human mammal having a pathogenic brain infection are also disclosed. | 11-19-2015 |
20150366175 | HUMANIZED IL-15 ANIMALS - Genetically modified non-human animals comprising a humanized interleukin-15 (IL-15) gene. Cells, embryos, and non-human animals comprising a human IL-15 gene. Rodents that express humanized or human IL-15 protein. | 12-24-2015 |
20150366836 | METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATING COLORECTAL CANCER - The present invention is related to a method and pharmaceutical composition for treating colorectal cancer. The pharmaceutical composition comprises an effective amount of 16-hydroxy-cleroda-3,13-dine-15,16-olide as active ingredient, and a pharmaceutically acceptable carrier. The present method and pharmaceutical composition provides good efficacy in treating colorectal cancer. The present invention also establishes an animal model, which provides a better drug screening platform for the research. | 12-24-2015 |
20160000054 | HUMAN-DERIVED MUTANTS OF THE dSOD1 GENE IN DROSOPHILA AND METHODS OF MAKING AND USING - Genetic models of amyotrophic lateral sclerosis (ALS) are described, which can be used to identify novel treatments of ALS and therapeutic targets. Methods for making and using human-derived mutants of the | 01-07-2016 |
20160002302 | LIGHT-ACTIVATED CHIMERIC OPSINS AND METHODS OF USING THE SAME - Provided herein are compositions comprising light-activated chimeric proteins expressed on plasma membranes and methods of using the same to selectively depolarize excitatory or inhibitory neurons. | 01-07-2016 |
20160015010 | ANIMAL MODEL OF CHARCOT-MARIE-TOOTH DISEASE AS HSP27 MUTANT (S135F) CARRIER - The present invention relates to a HSP27 mutation (S135F) mediated Charcot-Marie-Tooth disease (CMT) animal model. Particularly, the vector expressing mutant HSP27 protein wherein the 135 | 01-21-2016 |
20160017298 | Mutants of Cre Recombinase - The present invention relates to mutants of Cre recombinase. | 01-21-2016 |
20160031837 | COMPOUNDS FOR INDUCING PROLIFERATION AND DIFFERENTIATION OF CELLS, AND METHODS OF USE THEREOF - The present invention provides methods of inducing proliferation of and/or differentiating cells comprising contacting cells with compounds within the methods of the invention. The present invention further provides cells obtainable by the methods of the invention. Liver disease affects more than 500 million people worldwide. Organ transplantation is the gold standard for treatment of liver failure, but organ shortages are acute. | 02-04-2016 |
20160032382 | Method for Diagnosing or Predicting a Non Syndromic Autosomal Recessive Optic Atrophy, or a Risk of a Non Syndromic Autosomal Recessive Optic Atrophy - The present invention relates to a method for diagnosing or predicting a non syndromic autosomal recessive optic atrophy, or a risk of a non syndromic autosomal recessive optic atrophy. | 02-04-2016 |
20160058917 | Adhesion Preventing Material - An object of the present invention is to provide an adhesion preventing material capable of preventing adhesion safely and efficiently. The present invention provides an adhesion preventing material comprised of a cell sheet containing mesothelial cells; an adhesion preventing method and organ regeneration promoting method each using the cell sheet containing mesothelial cells. | 03-03-2016 |
20160061818 | ISLET1 (ISL1) And Hearing Loss - Described are methods and compositions for increasing islet-1 (Isl1) activity (e.g., biological activity) and or expression (e.g., transcription and/or translation) in a biological cell and or in a subject. | 03-03-2016 |
20160113996 | TAFA4 COMPOUNDS AND USES THEREOF FOR TREATING PAIN - The present invention relates to novel compounds for use for preventing, alleviating or treating pain in a subject. Also herein described are pharmaceutical compositions, their preparation and uses as well as methods for preventing, alleviating or treating pain using such compounds and compositions. | 04-28-2016 |
20160120158 | COMPOSITIONS AND METHODS FOR THE STUDY AND TREATMENT OF ACUTE KIDNEY INJURY - The present invention relates to the field of nephrology. More specifically, the present invention provides compositions and methods useful for the study and treatment of acute kidney injury. In one embodiment, the present invention provides a knockout animal whose genome comprises a deletion of exon 2 and exon 3 of kelch-like ECH-associated protein 1 (KEAP1) in T-cells. In another embodiment, a method for treating a subject diagnosed with AKI comprising the steps of (a) isolating T-cells from the subject; (b) activating Nrf2 expression in the isolated T-cells; and (c) administering the T-cells back to the subject. | 05-05-2016 |
20160135438 | ISOLATION OF NOVEL AAV'S AND USES THEREOF - The invention in some aspects relates to isolated nucleic acids, compositions, and kits useful for identifying adeno-associated viruses in cells. In some aspects, the invention provides kits and methods for producing somatic transgenic animal models using recombinant AAV (rAAV) to an animal having at least one transgene that expresses a small interfering nucleic acid or at least one binding site for a miRNA. | 05-19-2016 |
20160143255 | Animal Models of Ataxia-Telangiectasia (A-T) - The present invention provides transgenic, large non-human animal models of Ataxia-Telangiectasia, as well as methods of using such animal models in the identification and characterization of therapies for Ataxia-Telangiectasia. | 05-26-2016 |
20160150767 | miRNA-REGULATED DIFFERENTIATION-DEPENDENT SELF-DELETING CASSETTE | 06-02-2016 |
20160166712 | MURINE WOUND MODEL FOR TESTING PATHOGEN VIRUENCE AND THERAPEUTIC EFFICACY | 06-16-2016 |
20160174532 | GENETICALLY MODIFIED RAT MODELS FOR PAIN | 06-23-2016 |
20160174534 | GENETICALLY MODIFIED RAT MODELS FOR PHARMACOKINETICS | 06-23-2016 |
20160192626 | Method For Creating Endometriotic Cells And Endometriosis Model Animal | 07-07-2016 |
20160192627 | HUMANIZED MICE EXPRESSING THE PYRIN DOMAIN ONLY PROTEIN 2 | 07-07-2016 |
20160374319 | TRANSGENIC NON-HUMAN MAMMAL THAT EXPRESSES HUMAN MMP2 - A transgenic non-human mammal has a genome that includes an early-immediate enhancer of human cytomegalovirus (CMV enhancer), a β-actin promoter and the entire gene region of human matrix metalloproteinase 2 (hMMP2) disposed downstream of the promoter. The hMMP2 is systemically expressed in the transgenic non-human mammal, which thus provides a suitable animal model for studying chronic obstructive pulmonary disease and related diseases and conditions. | 12-29-2016 |